A new case report involving lanreotide was published on July 30, 2026, in Frontiers in Cardiovascular Medicine. The publication is titled "Fluctuating hypertension possibly leading to severe cardiomyopathy in SDHB-associated hereditary paraganglioma: from heart transplant candidacy to long-term lanreotide management: a case report."
The report describes a clinical case involving SDHB-associated hereditary paraganglioma, fluctuating hypertension, and cardiomyopathy, tracing a course that included consideration of heart transplant candidacy and long-term management with lanreotide. It is indexed under PubMed ID 42597314.
This entry is a publication record only. No efficacy, safety outcomes, or clinical results beyond the title and journal information have been provided here. Readers interested in the full findings, methodology, or clinical details should consult the original article directly through the listed source.
Lanreotide remains an approved compound, and this case report represents one documented instance of its use in a specific clinical context as described by the study authors. For general background on lanreotide, including its approved uses and mechanism, readers can consult the compound overview.